138 related articles for article (PubMed ID: 11012149)
1. Differences between normal and CML stem cells: potential targets for clinical exploitation.
Eaves AC; Barnett MJ; Ponchio L; Cashman JD; Petzer AL; Eaves CJ
Stem Cells; 1998; 16 Suppl 1():77-83; discussion 89. PubMed ID: 11012149
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor modulation of the inhibitory effect of transforming growth factor-beta on normal and leukemic human hematopoietic progenitor cells.
Cashman JD; Eaves AC; Eaves CJ
Leukemia; 1992 Sep; 6(9):886-92. PubMed ID: 1518302
[TBL] [Abstract][Full Text] [Related]
3. Biological strategies for the selective manipulation of normal and leukemic stem cells.
Eaves CJ; Cashman JD; Zoumbos NC; Barnett MJ; Eaves AC
Stem Cells; 1993 Oct; 11 Suppl 3():109-21. PubMed ID: 7905319
[TBL] [Abstract][Full Text] [Related]
4. The human hematopoietic stem cell in vitro and in vivo.
Eaves CJ; Sutherland HJ; Udomsakdi C; Lansdorp PM; Szilvassy SJ; Fraser CC; Humphries RK; Barnett MJ; Phillips GL; Eaves AC
Blood Cells; 1992; 18(2):301-7. PubMed ID: 1360270
[TBL] [Abstract][Full Text] [Related]
5. Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
Richter K; Pinto do O P; Hägglund AC; Wahlin A; Carlsson L
Haematologica; 2003 Dec; 88(12):1336-47. PubMed ID: 14687986
[TBL] [Abstract][Full Text] [Related]
6. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
[TBL] [Abstract][Full Text] [Related]
7. Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro.
Eaves C; Eaves A
Blood Cells; 1994; 20(1):83-93; discussion 93-5. PubMed ID: 7994064
[TBL] [Abstract][Full Text] [Related]
8. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.
Eisterer W; Jiang X; Christ O; Glimm H; Lee KH; Pang E; Lambie K; Shaw G; Holyoake TL; Petzer AL; Auewarakul C; Barnett MJ; Eaves CJ; Eaves AC
Leukemia; 2005 Mar; 19(3):435-41. PubMed ID: 15674418
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Schultheis B; Pasternak G; Hehlmann R
Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
[TBL] [Abstract][Full Text] [Related]
10. Discordant maturation as the primary biological defect in chronic myelogenous leukemia.
Strife A; Lambek C; Wisniewski D; Wachter M; Gulati SC; Clarkson BD
Cancer Res; 1988 Feb; 48(4):1035-41. PubMed ID: 3422181
[TBL] [Abstract][Full Text] [Related]
11. In vitro culture of bone marrow cells for autografting in CML.
Eaves CJ; Barnett MJ; Eaves AC
Leukemia; 1993 Aug; 7 Suppl 2():S126-9. PubMed ID: 8361215
[TBL] [Abstract][Full Text] [Related]
12. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
[TBL] [Abstract][Full Text] [Related]
14. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
15. Bestatin selectively suppresses the growth of leukemic stem/progenitor cells with BCR/ABL mRNA transcript in patients with chronic myelogeneous leukemia.
Fujisaki T; Otsuka T; Gondo H; Okamura T; Niho Y; Ohhinata A; Abe F
Int Immunopharmacol; 2003 Jun; 3(6):901-7. PubMed ID: 12781706
[TBL] [Abstract][Full Text] [Related]
16. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess.
Madlambayan GJ; Rogers I; Purpura KA; Ito C; Yu M; Kirouac D; Casper RF; Zandstra PW
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1020-30. PubMed ID: 17084368
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.
Rizzo MT; Regazzi E; Garau D; Akard L; Dugan M; Boswell HS; Rizzoli V; Carlo-Stella C
Cancer Res; 1999 Oct; 59(19):5047-53. PubMed ID: 10519422
[TBL] [Abstract][Full Text] [Related]
19. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
20. Integrin engagement-induced inhibition of human myelopoiesis is mediated by proline-rich tyrosine kinase 2 gene products.
Dylla SJ; Deyle DR; Theunissen K; Padurean AM; Verfaillie CM
Exp Hematol; 2004 Apr; 32(4):365-74. PubMed ID: 15050747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
